Ruben Mesa, MD

Articles

Clinical Pearls for the Management of Myelofibrosis

June 23rd 2022

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Myelofibrosis: Novel Combination Strategies

June 16th 2022

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

Novel Agents in the Pipeline for Myelofibrosis

June 16th 2022

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Myelofibrosis: Use of Fedratinib and Pacritinib Therapy

June 2nd 2022

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Use of Ruxolitinib in Myelofibrosis

June 2nd 2022

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

Historical Approaches to the Management of MF

May 26th 2022

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Factors in Selecting Therapy for Myelofibrosis

May 26th 2022

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Polycythemia Vera: Ruxolitinib Use and Goals of Therapy

May 5th 2022

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Treatment Armamentarium for Polycythemia Vera

May 5th 2022

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Dr. Mesa on Determinants of Disparities in Cancer Care

May 3rd 2022

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Making a Differential Diagnosis of Polycythemia Vera

April 28th 2022

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Dr. Mesa on the Importance of Community Engagement for Optimal Care in Oncology

February 10th 2022

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.